Charles Schwab Investment Management Inc. lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 3.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 616,153 shares of the company’s stock after acquiring an additional 21,157 shares during the period. Charles Schwab Investment Management Inc. owned 1.33% of Omnicell worth $27,431,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC raised its stake in Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after purchasing an additional 273 shares during the period. Van ECK Associates Corp increased its holdings in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after buying an additional 315 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares during the last quarter. KBC Group NV raised its position in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after buying an additional 778 shares during the period. Finally, CIBC Asset Management Inc acquired a new position in Omnicell in the fourth quarter valued at approximately $201,000. Institutional investors and hedge funds own 97.70% of the company’s stock.
Omnicell Price Performance
Shares of OMCL opened at $33.22 on Tuesday. The company has a market cap of $1.55 billion, a P/E ratio of 123.04, a PEG ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm’s 50 day moving average price is $40.48 and its 200 day moving average price is $43.18.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the company. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research note on Thursday, March 6th. Benchmark reissued a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. JPMorgan Chase & Co. upped their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Wells Fargo & Company dropped their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Bank of America reduced their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Omnicell has a consensus rating of “Hold” and an average target price of $52.33.
View Our Latest Analysis on Omnicell
Omnicell Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Stories
- Five stocks we like better than Omnicell
- Canadian Penny Stocks: Can They Make You Rich?
- Can TikTok Stock Picks Really Make You Rich?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- The “Quality” Rotation: Back to Basics Investing
- What Do S&P 500 Stocks Tell Investors About the Market?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.